Skip to main content
Top
Published in: BMC Cancer 1/2021

Open Access 01-12-2021 | Human Papillomavirus | Research article

Prediction of the local treatment outcome in patients with oropharyngeal squamous cell carcinoma using deep learning analysis of pretreatment FDG-PET images

Authors: Noriyuki Fujima, V. Carlota Andreu-Arasa, Sara K. Meibom, Gustavo A. Mercier, Minh Tam Truong, Kenji Hirata, Koichi Yasuda, Satoshi Kano, Akihiro Homma, Kohsuke Kudo, Osamu Sakai

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Background

This study aimed to assess the utility of deep learning analysis using pretreatment FDG-PET images to predict local treatment outcome in oropharyngeal squamous cell carcinoma (OPSCC) patients.

Methods

One hundred fifty-four OPSCC patients who received pretreatment FDG-PET were included and divided into training (n = 102) and test (n = 52) sets. The diagnosis of local failure and local progression-free survival (PFS) rates were obtained from patient medical records. In deep learning analyses, axial and coronal images were assessed by three different architectures (AlexNet, GoogLeNET, and ResNet). In the training set, FDG-PET images were analyzed after the data augmentation process for the diagnostic model creation. A multivariate clinical model was also created using a binomial logistic regression model from a patient’s clinical characteristics. The test data set was subsequently analyzed for confirmation of diagnostic accuracy. Assessment of local PFS rates was also performed.

Results

Training sessions were successfully performed with an accuracy of 74–89%. ROC curve analyses revealed an AUC of 0.61–0.85 by the deep learning model in the test set, whereas it was 0.62 by T-stage, 0.59 by clinical stage, and 0.74 by a multivariate clinical model. The highest AUC (0.85) was obtained with deep learning analysis of ResNet architecture. Cox proportional hazards regression analysis revealed deep learning-based classification by a multivariate clinical model (P < .05), and ResNet (P < .001) was a significant predictor of the treatment outcome. In the Kaplan-Meier analysis, the deep learning-based classification divided the patient’s local PFS rate better than the T-stage, clinical stage, and a multivariate clinical model.

Conclusions

Deep learning-based diagnostic model with FDG-PET images indicated its possibility to predict local treatment outcomes in OPSCCs.
Appendix
Available only for authorised users
Literature
22.
go back to reference Fujima N, Shimizu Y, Yoshida D, Kano S, Mizumachi T, Homma A, et al. Machine-learning-based prediction of treatment outcomes using MR imaging-derived quantitative tumor information in patients with Sinonasal squamous cell carcinomas: a preliminary study. Cancers (Basel). 2019;11(6):800. https://doi.org/10.3390/cancers11060800.CrossRef Fujima N, Shimizu Y, Yoshida D, Kano S, Mizumachi T, Homma A, et al. Machine-learning-based prediction of treatment outcomes using MR imaging-derived quantitative tumor information in patients with Sinonasal squamous cell carcinomas: a preliminary study. Cancers (Basel). 2019;11(6):800. https://​doi.​org/​10.​3390/​cancers11060800.CrossRef
Metadata
Title
Prediction of the local treatment outcome in patients with oropharyngeal squamous cell carcinoma using deep learning analysis of pretreatment FDG-PET images
Authors
Noriyuki Fujima
V. Carlota Andreu-Arasa
Sara K. Meibom
Gustavo A. Mercier
Minh Tam Truong
Kenji Hirata
Koichi Yasuda
Satoshi Kano
Akihiro Homma
Kohsuke Kudo
Osamu Sakai
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-08599-6

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine